Floatz logo

HUMAN FIBRINOGEN

Coagulopathy

University Health Network, Torontoprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Coagulopathy cohort.

Asset / SponsorPhaseRating
Damoctocog Alfa Pegol
Bayer
Phase 4BBB
Rivaroxaban
Brigham and Women's Hospital
Phase 4BBB
WARFARIN
Asan Medical Center
Phase 4BBB
Recombinant Human Plasminogen Activator
Hamilton Health Sciences Corporation
Phase 4BB
Pcc
University Health Network, Toronto
Phase 4BB

View all 24 →

Same molecule, other indications

HUMAN FIBRINOGEN is also rated in:

Traumatic HemorrhageDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
periampullary adenocarcinomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →